WO2023281419 - ADMINISTRATION OF NAKED NUCLEIC ACID MOLECULE
National phase entry:
Publication Number
WO/2023/281419
Publication Date
12.01.2023
International Application No.
PCT/IB2022/056252
International Filing Date
06.07.2022
Title **
[English]
ADMINISTRATION OF NAKED NUCLEIC ACID MOLECULE
[French]
ADMINISTRATION DE MOLÉCULE D'ACIDE NUCLÉIQUE NUE
Applicants **
DAICEL CORPORATION
2-18-1, Konan
Minato-ku, Tokyo 108-8230, JP
Inventors
SAKAGUCHI, Naoki
c/o Daicel Corporation
2-18-1, Konan
Minato-ku, Tokyo 108-8230, JP
YAMASHITA, Kunihiko
c/o Daicel Corporation
2-18-1, Konan
Minato-ku, Tokyo 108-8230, JP
Priority Data
63/218,899
06.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1133 | |
| EPO | Filing, Examination | 4619 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 9628 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein is a method of administering a naked nucleic acid molecule to a subject. The method may include injecting the naked nucleic acid molecule to the subject, wherein the injecting exhibits a bi-phasic injection profile comprising a first phase and a second phase, the second phase being after the first phase, and the bi-phasic injection profile has (i) at least two peaks within 15 msec from the injecting, (ii) the first peak of at least 2 MPa, or (iii) the highest peak of the second phase of the bi-phasic injection within 30 msec from the injecting.